Literature DB >> 24720272

Imbalances of CD4(+) T-cell subgroups in Crohn's disease and their relationship with disease activity and prognosis.

Kang Chao1, Shenghong Zhang, Jiayan Yao, Yao He, Baili Chen, Zhirong Zeng, Bihui Zhong, Minhu Chen.   

Abstract

BACKGROUND AND AIM: The CD4(+) T-cell subgroups play central pathophysiological roles in Crohn's disease (CD); however, their clinical relevance requires additional clarification and remains controversial. We investigated their balance in Chinese CD patients and explored their clinical significance.
METHODS: Peripheral blood mononuclear cells and serum were collected from 46 Chinese CD patients and 23 healthy donors. Circulating Treg, Th1, Th2, and Th17 cells were flow cytometrically analyzed. Subgroup-restricted transcription factor expression was determined by real-time polymerase chain reaction. Serum concentrations of the main cytokines produced by each subgroup were measured by cytometric bead arrays or enzyme-linked immunosorbent assay.
RESULTS: Lower Treg proportion (6.0 ± 1.2% vs 7.8 ± 1.5%, P = 0.030), FOXP3 mRNA expression (0.58-fold, P = 0.030), and circulating soluble TGFβ-1 (19.1 ± 9.9 vs 32.7 ± 16.8 ng/mL, P = 0.038) were observed in CD patients versus controls. The Th1 and Th17 proportions were higher in CD patients (17.8 ± 6.6% vs 7.8 ± 1.5%, P < 0.001; and 3.7 ± 1.8% vs 1.8 ± 0.7%, P = 0.022, respectively), as were transcription factors T-bet (4.6-fold, P = 0.043) and RORγt (14-fold, P < 0.001) and related cytokines (P < 0.05). Th2 proportion, GATA3 mRNA expression, and serum interleukin-4 concentration in CD patients were similar to controls (P > 0.05). Treg/Th1 and Treg/Th17 ratios were higher in inactive versus active CD patients (0.6 ± 0.4 vs 0.3 ± 0.1, P = 0.022; and 3.7 ± 2.0 vs 1.7 ± 1.4, P = 0.013, respectively). During follow-up, patients with lower Treg/Th1 and Treg/Th17 ratios were at higher recurrence risk.
CONCLUSIONS: Imbalances among Treg, Th1, and Th17 subgroups were found in Chinese CD patients. Treg/Th1 and Treg/Th17 ratios are associated with disease activity and are potential prognostic indicators for predicting CD recurrence.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Crohn's disease; Th cell; Treg cell; recurrence; transcription factors

Mesh:

Substances:

Year:  2014        PMID: 24720272     DOI: 10.1111/jgh.12592

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  21 in total

Review 1.  Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases.

Authors:  Bojana Simovic Markovic; Tatjana Kanjevac; C Randall Harrell; Marina Gazdic; Crissy Fellabaum; Nebojsa Arsenijevic; Vladislav Volarevic
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

2.  Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis.

Authors:  Padhmanand Sudhakar; Bram Verstockt; Jonathan Cremer; Sare Verstockt; João Sabino; Marc Ferrante; Séverine Vermeire
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 5.325

3.  Reduced incidence of Crohn's disease in systemic sclerosis: a nationwide population study.

Authors:  Chia-Chun Tseng; Jeng-Hsien Yen; Wen-Chan Tsai; Tsan-Teng Ou; Cheng-Chin Wu; Wan-Yu Sung; Ming-Chia Hsieh; Shun-Jen Chang
Journal:  BMC Musculoskelet Disord       Date:  2015-09-14       Impact factor: 2.362

Review 4.  Th17 cells in autoimmune and infectious diseases.

Authors:  José Francisco Zambrano-Zaragoza; Enrique Jhonatan Romo-Martínez; Ma de Jesús Durán-Avelar; Noemí García-Magallanes; Norberto Vibanco-Pérez
Journal:  Int J Inflam       Date:  2014-08-03

5.  Th17 Pathway As a Target for Multipotent Stromal Cell Therapy in Dogs: Implications for Translational Research.

Authors:  A Kol; N J Walker; M Nordstrom; D L Borjesson
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 6.  Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease.

Authors:  Fei Mao; Qiang Tu; Li Wang; Fuliang Chu; Xia Li; Haiyan S Li; Wenrong Xu
Journal:  Oncotarget       Date:  2017-06-06

7.  Suppression of Th17 Cell Response in the Alleviation of Dextran Sulfate Sodium-Induced Colitis by Ganoderma lucidum Polysaccharides.

Authors:  Bing Wei; Ran Zhang; Jingbo Zhai; Junfeng Zhu; Fangli Yang; Dan Yue; Xiaoyi Liu; Changlong Lu; Xun Sun
Journal:  J Immunol Res       Date:  2018-05-20       Impact factor: 4.818

8.  Pro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease.

Authors:  Huiling Wang; Kang Chao; Siew Chien Ng; Alfa Hc Bai; Qiao Yu; Jun Yu; Manying Li; Yi Cui; Minhu Chen; Ji-Fan Hu; Shenghong Zhang
Journal:  Genome Biol       Date:  2016-03-30       Impact factor: 13.583

Review 9.  Mechanisms of Microbe-Host Interaction in Crohn's Disease: Dysbiosis vs. Pathobiont Selection.

Authors:  Ludovica F Buttó; Monika Schaubeck; Dirk Haller
Journal:  Front Immunol       Date:  2015-11-19       Impact factor: 7.561

10.  Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5(+) B regulatory cells.

Authors:  Kang Chao; Shenghong Zhang; Yun Qiu; Xiaoyong Chen; Xiaoran Zhang; Chuang Cai; Yanwen Peng; Ren Mao; Meirav Pevsner-Fischer; Shomron Ben-Horin; Eran Elinav; Zhirong Zeng; Baili Chen; Yao He; Andy Peng Xiang; Minhu Chen
Journal:  Stem Cell Res Ther       Date:  2016-08-11       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.